nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA1—renal system—kidney cancer	0.0158	0.0851	CbGeAlD
Lithium—IMPA1—kidney—kidney cancer	0.0153	0.0823	CbGeAlD
Lithium—IMPA1—gonad—kidney cancer	0.0142	0.0763	CbGeAlD
Lithium—IMPA2—nephron tubule—kidney cancer	0.013	0.0703	CbGeAlD
Lithium—IMPA2—renal system—kidney cancer	0.0119	0.0639	CbGeAlD
Lithium—GSK3B—renal system—kidney cancer	0.0116	0.0627	CbGeAlD
Lithium—IMPA2—kidney—kidney cancer	0.0115	0.0618	CbGeAlD
Lithium—GSK3B—kidney—kidney cancer	0.0112	0.0606	CbGeAlD
Lithium—IMPA2—cortex of kidney—kidney cancer	0.0112	0.0601	CbGeAlD
Lithium—GSK3A—nephron tubule—kidney cancer	0.0111	0.0599	CbGeAlD
Lithium—IMPA2—cardiac atrium—kidney cancer	0.0106	0.0572	CbGeAlD
Lithium—GSK3B—gonad—kidney cancer	0.0104	0.0562	CbGeAlD
Lithium—GSK3A—renal system—kidney cancer	0.0101	0.0545	CbGeAlD
Lithium—GSK3A—cortex of kidney—kidney cancer	0.00952	0.0513	CbGeAlD
Lithium—GSK3A—gonad—kidney cancer	0.00907	0.0489	CbGeAlD
Lithium—GSK3A—cardiac atrium—kidney cancer	0.00906	0.0488	CbGeAlD
Lithium—Muscular weakness—Capecitabine—kidney cancer	0.000488	0.00144	CcSEcCtD
Lithium—Feeling abnormal—Everolimus—kidney cancer	0.000487	0.00144	CcSEcCtD
Lithium—Shock—Sunitinib—kidney cancer	0.000485	0.00143	CcSEcCtD
Lithium—Gastrointestinal pain—Vinblastine—kidney cancer	0.000485	0.00143	CcSEcCtD
Lithium—Gastrointestinal pain—Everolimus—kidney cancer	0.000483	0.00143	CcSEcCtD
Lithium—Discomfort—Dactinomycin—kidney cancer	0.000481	0.00142	CcSEcCtD
Lithium—Salivary hypersecretion—Doxorubicin—kidney cancer	0.000477	0.00141	CcSEcCtD
Lithium—Vomiting—Pazopanib—kidney cancer	0.000476	0.0014	CcSEcCtD
Lithium—Bradycardia—Paclitaxel—kidney cancer	0.000475	0.0014	CcSEcCtD
Lithium—Rash—Pazopanib—kidney cancer	0.000472	0.00139	CcSEcCtD
Lithium—Nausea—Temsirolimus—kidney cancer	0.000472	0.00139	CcSEcCtD
Lithium—Dermatitis—Pazopanib—kidney cancer	0.000471	0.00139	CcSEcCtD
Lithium—Anorexia—Sunitinib—kidney cancer	0.00047	0.00139	CcSEcCtD
Lithium—Agitation—Vincristine—kidney cancer	0.00047	0.00139	CcSEcCtD
Lithium—Abdominal pain—Vinblastine—kidney cancer	0.000469	0.00138	CcSEcCtD
Lithium—Headache—Pazopanib—kidney cancer	0.000469	0.00138	CcSEcCtD
Lithium—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.000467	0.00138	CcSEcCtD
Lithium—Oedema—Dactinomycin—kidney cancer	0.000467	0.00138	CcSEcCtD
Lithium—Abdominal pain—Everolimus—kidney cancer	0.000467	0.00138	CcSEcCtD
Lithium—Body temperature increased—Everolimus—kidney cancer	0.000467	0.00138	CcSEcCtD
Lithium—Gastrointestinal pain—Erlotinib—kidney cancer	0.000466	0.00138	CcSEcCtD
Lithium—Vertigo—Vincristine—kidney cancer	0.000459	0.00136	CcSEcCtD
Lithium—Dyspepsia—Sorafenib—kidney cancer	0.000451	0.00133	CcSEcCtD
Lithium—Body temperature increased—Erlotinib—kidney cancer	0.000451	0.00133	CcSEcCtD
Lithium—Abdominal pain—Erlotinib—kidney cancer	0.000451	0.00133	CcSEcCtD
Lithium—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.00045	0.00133	CcSEcCtD
Lithium—Coma—Doxorubicin—kidney cancer	0.000449	0.00133	CcSEcCtD
Lithium—Decreased appetite—Sorafenib—kidney cancer	0.000446	0.00132	CcSEcCtD
Lithium—Anorexia—Dactinomycin—kidney cancer	0.000445	0.00131	CcSEcCtD
Lithium—Nausea—Pazopanib—kidney cancer	0.000444	0.00131	CcSEcCtD
Lithium—Convulsion—Vincristine—kidney cancer	0.000443	0.00131	CcSEcCtD
Lithium—Fatigue—Sorafenib—kidney cancer	0.000442	0.0013	CcSEcCtD
Lithium—Weight increased—Capecitabine—kidney cancer	0.000435	0.00128	CcSEcCtD
Lithium—Tinnitus—Paclitaxel—kidney cancer	0.000435	0.00128	CcSEcCtD
Lithium—Dyspepsia—Sunitinib—kidney cancer	0.000434	0.00128	CcSEcCtD
Lithium—Weight decreased—Capecitabine—kidney cancer	0.000433	0.00128	CcSEcCtD
Lithium—Hyperglycaemia—Capecitabine—kidney cancer	0.000432	0.00127	CcSEcCtD
Lithium—Hypertonia—Doxorubicin—kidney cancer	0.000431	0.00127	CcSEcCtD
Lithium—Decreased appetite—Sunitinib—kidney cancer	0.000429	0.00127	CcSEcCtD
Lithium—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000426	0.00126	CcSEcCtD
Lithium—Asthenia—Vinblastine—kidney cancer	0.000426	0.00126	CcSEcCtD
Lithium—Fatigue—Sunitinib—kidney cancer	0.000425	0.00126	CcSEcCtD
Lithium—Asthenia—Everolimus—kidney cancer	0.000424	0.00125	CcSEcCtD
Lithium—Gastrointestinal pain—Sorafenib—kidney cancer	0.000419	0.00124	CcSEcCtD
Lithium—Oedema—Vincristine—kidney cancer	0.000417	0.00123	CcSEcCtD
Lithium—Arrhythmia—Paclitaxel—kidney cancer	0.000417	0.00123	CcSEcCtD
Lithium—Arthralgia—Gemcitabine—kidney cancer	0.000413	0.00122	CcSEcCtD
Lithium—Alopecia—Paclitaxel—kidney cancer	0.000412	0.00122	CcSEcCtD
Lithium—Asthenia—Erlotinib—kidney cancer	0.000409	0.00121	CcSEcCtD
Lithium—Discomfort—Gemcitabine—kidney cancer	0.000408	0.0012	CcSEcCtD
Lithium—Decreased appetite—Dactinomycin—kidney cancer	0.000406	0.0012	CcSEcCtD
Lithium—Diarrhoea—Vinblastine—kidney cancer	0.000406	0.0012	CcSEcCtD
Lithium—Body temperature increased—Sorafenib—kidney cancer	0.000405	0.0012	CcSEcCtD
Lithium—Abdominal pain—Sorafenib—kidney cancer	0.000405	0.0012	CcSEcCtD
Lithium—Diarrhoea—Everolimus—kidney cancer	0.000404	0.00119	CcSEcCtD
Lithium—Gastrointestinal pain—Sunitinib—kidney cancer	0.000404	0.00119	CcSEcCtD
Lithium—Fatigue—Dactinomycin—kidney cancer	0.000403	0.00119	CcSEcCtD
Lithium—Flatulence—Paclitaxel—kidney cancer	0.0004	0.00118	CcSEcCtD
Lithium—Anorexia—Vincristine—kidney cancer	0.000398	0.00117	CcSEcCtD
Lithium—Dysgeusia—Paclitaxel—kidney cancer	0.000398	0.00117	CcSEcCtD
Lithium—Oedema—Gemcitabine—kidney cancer	0.000396	0.00117	CcSEcCtD
Lithium—Dizziness—Vinblastine—kidney cancer	0.000392	0.00116	CcSEcCtD
Lithium—Dizziness—Everolimus—kidney cancer	0.000391	0.00115	CcSEcCtD
Lithium—Abdominal pain—Sunitinib—kidney cancer	0.00039	0.00115	CcSEcCtD
Lithium—Body temperature increased—Sunitinib—kidney cancer	0.00039	0.00115	CcSEcCtD
Lithium—Diarrhoea—Erlotinib—kidney cancer	0.00039	0.00115	CcSEcCtD
Lithium—Hypotension—Vincristine—kidney cancer	0.00039	0.00115	CcSEcCtD
Lithium—Bradycardia—Capecitabine—kidney cancer	0.00039	0.00115	CcSEcCtD
Lithium—Feeling abnormal—Dactinomycin—kidney cancer	0.000385	0.00114	CcSEcCtD
Lithium—Vision blurred—Paclitaxel—kidney cancer	0.000383	0.00113	CcSEcCtD
Lithium—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000382	0.00113	CcSEcCtD
Lithium—Tremor—Paclitaxel—kidney cancer	0.000381	0.00112	CcSEcCtD
Lithium—Musculoskeletal discomfort—Vincristine—kidney cancer	0.00038	0.00112	CcSEcCtD
Lithium—Anorexia—Gemcitabine—kidney cancer	0.000377	0.00111	CcSEcCtD
Lithium—Vomiting—Vinblastine—kidney cancer	0.000377	0.00111	CcSEcCtD
Lithium—Dizziness—Erlotinib—kidney cancer	0.000377	0.00111	CcSEcCtD
Lithium—Vomiting—Everolimus—kidney cancer	0.000376	0.00111	CcSEcCtD
Lithium—Agitation—Paclitaxel—kidney cancer	0.000373	0.0011	CcSEcCtD
Lithium—Rash—Everolimus—kidney cancer	0.000372	0.0011	CcSEcCtD
Lithium—Dermatitis—Everolimus—kidney cancer	0.000372	0.0011	CcSEcCtD
Lithium—Headache—Vinblastine—kidney cancer	0.000372	0.0011	CcSEcCtD
Lithium—Angioedema—Paclitaxel—kidney cancer	0.000371	0.00109	CcSEcCtD
Lithium—Headache—Everolimus—kidney cancer	0.00037	0.00109	CcSEcCtD
Lithium—Hypotension—Gemcitabine—kidney cancer	0.00037	0.00109	CcSEcCtD
Lithium—Abdominal pain—Dactinomycin—kidney cancer	0.000369	0.00109	CcSEcCtD
Lithium—Body temperature increased—Dactinomycin—kidney cancer	0.000369	0.00109	CcSEcCtD
Lithium—Asthenia—Sorafenib—kidney cancer	0.000368	0.00109	CcSEcCtD
Lithium—Vertigo—Paclitaxel—kidney cancer	0.000365	0.00108	CcSEcCtD
Lithium—Syncope—Paclitaxel—kidney cancer	0.000364	0.00107	CcSEcCtD
Lithium—Lethargy—Doxorubicin—kidney cancer	0.000364	0.00107	CcSEcCtD
Lithium—Decreased appetite—Vincristine—kidney cancer	0.000363	0.00107	CcSEcCtD
Lithium—Vomiting—Erlotinib—kidney cancer	0.000362	0.00107	CcSEcCtD
Lithium—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000361	0.00106	CcSEcCtD
Lithium—Fatigue—Vincristine—kidney cancer	0.00036	0.00106	CcSEcCtD
Lithium—Rash—Erlotinib—kidney cancer	0.000359	0.00106	CcSEcCtD
Lithium—Dermatitis—Erlotinib—kidney cancer	0.000359	0.00106	CcSEcCtD
Lithium—Headache—Erlotinib—kidney cancer	0.000357	0.00105	CcSEcCtD
Lithium—Tinnitus—Capecitabine—kidney cancer	0.000357	0.00105	CcSEcCtD
Lithium—Loss of consciousness—Paclitaxel—kidney cancer	0.000357	0.00105	CcSEcCtD
Lithium—Asthenia—Sunitinib—kidney cancer	0.000354	0.00104	CcSEcCtD
Lithium—Nausea—Vinblastine—kidney cancer	0.000352	0.00104	CcSEcCtD
Lithium—Somnolence—Gemcitabine—kidney cancer	0.000352	0.00104	CcSEcCtD
Lithium—Convulsion—Paclitaxel—kidney cancer	0.000352	0.00104	CcSEcCtD
Lithium—Nausea—Everolimus—kidney cancer	0.000351	0.00104	CcSEcCtD
Lithium—Diarrhoea—Sorafenib—kidney cancer	0.000351	0.00104	CcSEcCtD
Lithium—Arthralgia—Paclitaxel—kidney cancer	0.000346	0.00102	CcSEcCtD
Lithium—Decreased appetite—Gemcitabine—kidney cancer	0.000344	0.00102	CcSEcCtD
Lithium—Arrhythmia—Capecitabine—kidney cancer	0.000342	0.00101	CcSEcCtD
Lithium—Discomfort—Paclitaxel—kidney cancer	0.000342	0.00101	CcSEcCtD
Lithium—Fatigue—Gemcitabine—kidney cancer	0.000341	0.00101	CcSEcCtD
Lithium—Gastrointestinal pain—Vincristine—kidney cancer	0.000341	0.00101	CcSEcCtD
Lithium—Dizziness—Sorafenib—kidney cancer	0.000339	0.001	CcSEcCtD
Lithium—Nausea—Erlotinib—kidney cancer	0.000339	0.000999	CcSEcCtD
Lithium—Alopecia—Capecitabine—kidney cancer	0.000338	0.000998	CcSEcCtD
Lithium—Dry mouth—Paclitaxel—kidney cancer	0.000338	0.000998	CcSEcCtD
Lithium—Diarrhoea—Sunitinib—kidney cancer	0.000338	0.000996	CcSEcCtD
Lithium—Ataxia—Doxorubicin—kidney cancer	0.000335	0.00099	CcSEcCtD
Lithium—Asthenia—Dactinomycin—kidney cancer	0.000335	0.000989	CcSEcCtD
Lithium—Confusional state—Paclitaxel—kidney cancer	0.000334	0.000986	CcSEcCtD
Lithium—Dehydration—Doxorubicin—kidney cancer	0.000332	0.000979	CcSEcCtD
Lithium—Oedema—Paclitaxel—kidney cancer	0.000332	0.000978	CcSEcCtD
Lithium—Abdominal pain—Vincristine—kidney cancer	0.00033	0.000973	CcSEcCtD
Lithium—Body temperature increased—Vincristine—kidney cancer	0.00033	0.000973	CcSEcCtD
Lithium—Flatulence—Capecitabine—kidney cancer	0.000328	0.000969	CcSEcCtD
Lithium—Dry skin—Doxorubicin—kidney cancer	0.000327	0.000965	CcSEcCtD
Lithium—Dysgeusia—Capecitabine—kidney cancer	0.000326	0.000963	CcSEcCtD
Lithium—Dizziness—Sunitinib—kidney cancer	0.000326	0.000963	CcSEcCtD
Lithium—Feeling abnormal—Gemcitabine—kidney cancer	0.000326	0.000963	CcSEcCtD
Lithium—Shock—Paclitaxel—kidney cancer	0.000326	0.000962	CcSEcCtD
Lithium—Vomiting—Sorafenib—kidney cancer	0.000326	0.000962	CcSEcCtD
Lithium—Rash—Sorafenib—kidney cancer	0.000323	0.000954	CcSEcCtD
Lithium—Dermatitis—Sorafenib—kidney cancer	0.000323	0.000953	CcSEcCtD
Lithium—Headache—Sorafenib—kidney cancer	0.000321	0.000948	CcSEcCtD
Lithium—Diarrhoea—Dactinomycin—kidney cancer	0.00032	0.000943	CcSEcCtD
Lithium—Anorexia—Paclitaxel—kidney cancer	0.000316	0.000932	CcSEcCtD
Lithium—Gastritis—Doxorubicin—kidney cancer	0.000316	0.000932	CcSEcCtD
Lithium—Muscular weakness—Doxorubicin—kidney cancer	0.000315	0.000928	CcSEcCtD
Lithium—Vision blurred—Capecitabine—kidney cancer	0.000314	0.000927	CcSEcCtD
Lithium—Vomiting—Sunitinib—kidney cancer	0.000314	0.000926	CcSEcCtD
Lithium—Body temperature increased—Gemcitabine—kidney cancer	0.000313	0.000923	CcSEcCtD
Lithium—Tremor—Capecitabine—kidney cancer	0.000312	0.000921	CcSEcCtD
Lithium—Rash—Sunitinib—kidney cancer	0.000311	0.000918	CcSEcCtD
Lithium—Dermatitis—Sunitinib—kidney cancer	0.000311	0.000917	CcSEcCtD
Lithium—Hypotension—Paclitaxel—kidney cancer	0.00031	0.000914	CcSEcCtD
Lithium—Headache—Sunitinib—kidney cancer	0.000309	0.000912	CcSEcCtD
Lithium—Nausea—Sorafenib—kidney cancer	0.000305	0.000899	CcSEcCtD
Lithium—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000302	0.000891	CcSEcCtD
Lithium—Vertigo—Capecitabine—kidney cancer	0.000299	0.000884	CcSEcCtD
Lithium—Asthenia—Vincristine—kidney cancer	0.000299	0.000883	CcSEcCtD
Lithium—Syncope—Capecitabine—kidney cancer	0.000299	0.000882	CcSEcCtD
Lithium—Vomiting—Dactinomycin—kidney cancer	0.000297	0.000876	CcSEcCtD
Lithium—Somnolence—Paclitaxel—kidney cancer	0.000295	0.000869	CcSEcCtD
Lithium—Rash—Dactinomycin—kidney cancer	0.000295	0.000869	CcSEcCtD
Lithium—Nausea—Sunitinib—kidney cancer	0.000293	0.000865	CcSEcCtD
Lithium—Loss of consciousness—Capecitabine—kidney cancer	0.000293	0.000864	CcSEcCtD
Lithium—Dyspepsia—Paclitaxel—kidney cancer	0.000292	0.000861	CcSEcCtD
Lithium—Decreased appetite—Paclitaxel—kidney cancer	0.000288	0.00085	CcSEcCtD
Lithium—Fatigue—Paclitaxel—kidney cancer	0.000286	0.000843	CcSEcCtD
Lithium—Diarrhoea—Vincristine—kidney cancer	0.000286	0.000843	CcSEcCtD
Lithium—Asthenia—Gemcitabine—kidney cancer	0.000284	0.000838	CcSEcCtD
Lithium—Arthralgia—Capecitabine—kidney cancer	0.000284	0.000837	CcSEcCtD
Lithium—Weight increased—Doxorubicin—kidney cancer	0.000281	0.000828	CcSEcCtD
Lithium—Discomfort—Capecitabine—kidney cancer	0.00028	0.000827	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—kidney cancer	0.000279	0.000823	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—kidney cancer	0.000278	0.000821	CcSEcCtD
Lithium—Dry mouth—Capecitabine—kidney cancer	0.000278	0.000819	CcSEcCtD
Lithium—Nausea—Dactinomycin—kidney cancer	0.000277	0.000819	CcSEcCtD
Lithium—Dizziness—Vincristine—kidney cancer	0.000276	0.000814	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—kidney cancer	0.000275	0.000811	CcSEcCtD
Lithium—Confusional state—Capecitabine—kidney cancer	0.000274	0.000809	CcSEcCtD
Lithium—Feeling abnormal—Paclitaxel—kidney cancer	0.000273	0.000806	CcSEcCtD
Lithium—Oedema—Capecitabine—kidney cancer	0.000272	0.000803	CcSEcCtD
Lithium—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000271	0.0008	CcSEcCtD
Lithium—Diarrhoea—Gemcitabine—kidney cancer	0.000271	0.000799	CcSEcCtD
Lithium—Shock—Capecitabine—kidney cancer	0.000268	0.00079	CcSEcCtD
Lithium—Vomiting—Vincristine—kidney cancer	0.000265	0.000783	CcSEcCtD
Lithium—Rash—Vincristine—kidney cancer	0.000263	0.000776	CcSEcCtD
Lithium—Dermatitis—Vincristine—kidney cancer	0.000263	0.000776	CcSEcCtD
Lithium—Body temperature increased—Paclitaxel—kidney cancer	0.000262	0.000773	CcSEcCtD
Lithium—Abdominal pain—Paclitaxel—kidney cancer	0.000262	0.000773	CcSEcCtD
Lithium—Headache—Vincristine—kidney cancer	0.000261	0.000771	CcSEcCtD
Lithium—Anorexia—Capecitabine—kidney cancer	0.000259	0.000765	CcSEcCtD
Lithium—Hypotension—Capecitabine—kidney cancer	0.000254	0.00075	CcSEcCtD
Lithium—Vomiting—Gemcitabine—kidney cancer	0.000252	0.000743	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—kidney cancer	0.000251	0.000741	CcSEcCtD
Lithium—Rash—Gemcitabine—kidney cancer	0.00025	0.000737	CcSEcCtD
Lithium—Dermatitis—Gemcitabine—kidney cancer	0.000249	0.000736	CcSEcCtD
Lithium—Headache—Gemcitabine—kidney cancer	0.000248	0.000732	CcSEcCtD
Lithium—Nausea—Vincristine—kidney cancer	0.000248	0.000731	CcSEcCtD
Lithium—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000248	0.000731	CcSEcCtD
Lithium—Dyspepsia—Capecitabine—kidney cancer	0.000239	0.000707	CcSEcCtD
Lithium—Asthenia—Paclitaxel—kidney cancer	0.000238	0.000702	CcSEcCtD
Lithium—Decreased appetite—Capecitabine—kidney cancer	0.000236	0.000698	CcSEcCtD
Lithium—Nausea—Gemcitabine—kidney cancer	0.000235	0.000694	CcSEcCtD
Lithium—Fatigue—Capecitabine—kidney cancer	0.000235	0.000692	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—kidney cancer	0.00023	0.000679	CcSEcCtD
Lithium—Diarrhoea—Paclitaxel—kidney cancer	0.000227	0.000669	CcSEcCtD
Lithium—Feeling abnormal—Capecitabine—kidney cancer	0.000224	0.000661	CcSEcCtD
Lithium—Gastrointestinal pain—Capecitabine—kidney cancer	0.000222	0.000656	CcSEcCtD
Lithium—Arrhythmia—Doxorubicin—kidney cancer	0.00022	0.000651	CcSEcCtD
Lithium—Dizziness—Paclitaxel—kidney cancer	0.000219	0.000647	CcSEcCtD
Lithium—Alopecia—Doxorubicin—kidney cancer	0.000218	0.000643	CcSEcCtD
Lithium—Abdominal pain—Capecitabine—kidney cancer	0.000215	0.000634	CcSEcCtD
Lithium—Body temperature increased—Capecitabine—kidney cancer	0.000215	0.000634	CcSEcCtD
Lithium—Flatulence—Doxorubicin—kidney cancer	0.000212	0.000625	CcSEcCtD
Lithium—Vomiting—Paclitaxel—kidney cancer	0.000211	0.000622	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—kidney cancer	0.00021	0.000621	CcSEcCtD
Lithium—Rash—Paclitaxel—kidney cancer	0.000209	0.000617	CcSEcCtD
Lithium—Dermatitis—Paclitaxel—kidney cancer	0.000209	0.000616	CcSEcCtD
Lithium—Headache—Paclitaxel—kidney cancer	0.000208	0.000613	CcSEcCtD
Lithium—Vision blurred—Doxorubicin—kidney cancer	0.000202	0.000597	CcSEcCtD
Lithium—Agitation—Doxorubicin—kidney cancer	0.000197	0.000583	CcSEcCtD
Lithium—Nausea—Paclitaxel—kidney cancer	0.000197	0.000581	CcSEcCtD
Lithium—Asthenia—Capecitabine—kidney cancer	0.000195	0.000576	CcSEcCtD
Lithium—Vertigo—Doxorubicin—kidney cancer	0.000193	0.00057	CcSEcCtD
Lithium—Syncope—Doxorubicin—kidney cancer	0.000193	0.000568	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—kidney cancer	0.000189	0.000557	CcSEcCtD
Lithium—Convulsion—Doxorubicin—kidney cancer	0.000186	0.000549	CcSEcCtD
Lithium—Diarrhoea—Capecitabine—kidney cancer	0.000186	0.000549	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—kidney cancer	0.000183	0.00054	CcSEcCtD
Lithium—Discomfort—Doxorubicin—kidney cancer	0.000181	0.000533	CcSEcCtD
Lithium—Dizziness—Capecitabine—kidney cancer	0.00018	0.000531	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—kidney cancer	0.000179	0.000528	CcSEcCtD
Lithium—Confusional state—Doxorubicin—kidney cancer	0.000177	0.000522	CcSEcCtD
Lithium—Oedema—Doxorubicin—kidney cancer	0.000175	0.000517	CcSEcCtD
Lithium—Vomiting—Capecitabine—kidney cancer	0.000173	0.00051	CcSEcCtD
Lithium—Shock—Doxorubicin—kidney cancer	0.000173	0.000509	CcSEcCtD
Lithium—Rash—Capecitabine—kidney cancer	0.000172	0.000506	CcSEcCtD
Lithium—Dermatitis—Capecitabine—kidney cancer	0.000171	0.000506	CcSEcCtD
Lithium—Headache—Capecitabine—kidney cancer	0.00017	0.000503	CcSEcCtD
Lithium—Anorexia—Doxorubicin—kidney cancer	0.000167	0.000493	CcSEcCtD
Lithium—Hypotension—Doxorubicin—kidney cancer	0.000164	0.000483	CcSEcCtD
Lithium—Nausea—Capecitabine—kidney cancer	0.000162	0.000477	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.00016	0.000471	CcSEcCtD
Lithium—Somnolence—Doxorubicin—kidney cancer	0.000156	0.00046	CcSEcCtD
Lithium—Dyspepsia—Doxorubicin—kidney cancer	0.000154	0.000455	CcSEcCtD
Lithium—Decreased appetite—Doxorubicin—kidney cancer	0.000152	0.00045	CcSEcCtD
Lithium—Fatigue—Doxorubicin—kidney cancer	0.000151	0.000446	CcSEcCtD
Lithium—Feeling abnormal—Doxorubicin—kidney cancer	0.000145	0.000426	CcSEcCtD
Lithium—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000143	0.000423	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—kidney cancer	0.000139	0.000409	CcSEcCtD
Lithium—Abdominal pain—Doxorubicin—kidney cancer	0.000139	0.000409	CcSEcCtD
Lithium—Asthenia—Doxorubicin—kidney cancer	0.000126	0.000371	CcSEcCtD
Lithium—Diarrhoea—Doxorubicin—kidney cancer	0.00012	0.000354	CcSEcCtD
Lithium—Dizziness—Doxorubicin—kidney cancer	0.000116	0.000342	CcSEcCtD
Lithium—Vomiting—Doxorubicin—kidney cancer	0.000111	0.000329	CcSEcCtD
Lithium—Rash—Doxorubicin—kidney cancer	0.000111	0.000326	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—kidney cancer	0.00011	0.000326	CcSEcCtD
Lithium—Headache—Doxorubicin—kidney cancer	0.00011	0.000324	CcSEcCtD
Lithium—Nausea—Doxorubicin—kidney cancer	0.000104	0.000307	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—CDH1—kidney cancer	9.3e-05	0.000196	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—PIK3CA—kidney cancer	9.26e-05	0.000195	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ITPR2—kidney cancer	9.19e-05	0.000193	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—PIK3CA—kidney cancer	9.18e-05	0.000193	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—PIK3CA—kidney cancer	9.14e-05	0.000192	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTSB—kidney cancer	9.11e-05	0.000192	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTSD—kidney cancer	9.06e-05	0.000191	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PTEN—kidney cancer	9.03e-05	0.00019	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—MYC—kidney cancer	9.02e-05	0.00019	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KRAS—kidney cancer	9.01e-05	0.00019	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—PIK3CA—kidney cancer	8.83e-05	0.000186	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TSC2—kidney cancer	8.8e-05	0.000185	CbGpPWpGaD
Lithium—GSK3B—Immune System—PSMD7—kidney cancer	8.8e-05	0.000185	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—POMC—kidney cancer	8.75e-05	0.000184	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—VEGFA—kidney cancer	8.69e-05	0.000183	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—PIK3CA—kidney cancer	8.65e-05	0.000182	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—PIK3CA—kidney cancer	8.62e-05	0.000181	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—CTNNB1—kidney cancer	8.53e-05	0.000179	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—TSC2—kidney cancer	8.45e-05	0.000178	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—MYC—kidney cancer	8.38e-05	0.000176	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTEN—kidney cancer	8.33e-05	0.000175	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNA1—kidney cancer	8.33e-05	0.000175	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EIF4EBP1—kidney cancer	8.28e-05	0.000174	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HSPB1—kidney cancer	8.28e-05	0.000174	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—PIK3CA—kidney cancer	8.28e-05	0.000174	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—RAF1—kidney cancer	8.26e-05	0.000174	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—MAPK3—kidney cancer	8.22e-05	0.000173	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—RELA—kidney cancer	8.22e-05	0.000173	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ERBB2—kidney cancer	8.17e-05	0.000172	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—kidney cancer	8.17e-05	0.000172	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD8A—kidney cancer	8.16e-05	0.000172	CbGpPWpGaD
Lithium—GSK3B—Disease—PSMD7—kidney cancer	8.12e-05	0.000171	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—MTOR—kidney cancer	8.06e-05	0.00017	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CD4—kidney cancer	8.05e-05	0.000169	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN2B—kidney cancer	8.03e-05	0.000169	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP2—kidney cancer	7.98e-05	0.000168	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKAP13—kidney cancer	7.98e-05	0.000168	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—RAF1—kidney cancer	7.93e-05	0.000167	CbGpPWpGaD
Lithium—GSK3B—Immune System—PAK1—kidney cancer	7.9e-05	0.000166	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—RELA—kidney cancer	7.89e-05	0.000166	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ERBB2—kidney cancer	7.84e-05	0.000165	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—MAPK1—kidney cancer	7.82e-05	0.000165	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KIT—kidney cancer	7.77e-05	0.000164	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—MTOR—kidney cancer	7.74e-05	0.000163	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD4—kidney cancer	7.73e-05	0.000163	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—MAPK3—kidney cancer	7.71e-05	0.000162	CbGpPWpGaD
Lithium—GSK3B—Immune System—IFNA1—kidney cancer	7.71e-05	0.000162	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TSC1—kidney cancer	7.7e-05	0.000162	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PSMD7—kidney cancer	7.7e-05	0.000162	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ANXA1—kidney cancer	7.7e-05	0.000162	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CDKN1B—kidney cancer	7.57e-05	0.000159	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KIT—kidney cancer	7.47e-05	0.000157	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FLT1—kidney cancer	7.46e-05	0.000157	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGR1—kidney cancer	7.39e-05	0.000155	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—VEGFA—kidney cancer	7.38e-05	0.000155	CbGpPWpGaD
Lithium—GSK3B—Disease—SLC2A1—kidney cancer	7.35e-05	0.000155	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—MAPK1—kidney cancer	7.34e-05	0.000154	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GRB7—kidney cancer	7.3e-05	0.000154	CbGpPWpGaD
Lithium—GSK3B—Disease—JUNB—kidney cancer	7.29e-05	0.000153	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDKN1B—kidney cancer	7.26e-05	0.000153	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—JUN—kidney cancer	7.2e-05	0.000151	CbGpPWpGaD
Lithium—GSK3B—Immune System—IFNA2—kidney cancer	7.17e-05	0.000151	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CTNNB1—kidney cancer	7.15e-05	0.00015	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MAPK3—kidney cancer	6.98e-05	0.000147	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PTEN—kidney cancer	6.97e-05	0.000147	CbGpPWpGaD
Lithium—GSK3A—Immune System—TSC2—kidney cancer	6.94e-05	0.000146	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KRAS—kidney cancer	6.93e-05	0.000146	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PAK1—kidney cancer	6.91e-05	0.000145	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—JUNB—kidney cancer	6.91e-05	0.000145	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—RAF1—kidney cancer	6.91e-05	0.000145	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—MYC—kidney cancer	6.91e-05	0.000145	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—RELA—kidney cancer	6.88e-05	0.000145	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDH1—kidney cancer	6.87e-05	0.000145	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ERBB2—kidney cancer	6.84e-05	0.000144	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ITPR2—kidney cancer	6.79e-05	0.000143	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PTEN—kidney cancer	6.69e-05	0.000141	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MAPK1—kidney cancer	6.64e-05	0.00014	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PIK3CA—kidney cancer	6.6e-05	0.000139	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—kidney cancer	6.57e-05	0.000138	CbGpPWpGaD
Lithium—GSK3A—Disease—HIF1A—kidney cancer	6.42e-05	0.000135	CbGpPWpGaD
Lithium—GSK3A—Disease—TSC2—kidney cancer	6.41e-05	0.000135	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PIK3CA—kidney cancer	6.37e-05	0.000134	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KRAS—kidney cancer	6.27e-05	0.000132	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CTNNB1—kidney cancer	6.25e-05	0.000131	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNA1—kidney cancer	6.15e-05	0.000129	CbGpPWpGaD
Lithium—GSK3A—Immune System—KIT—kidney cancer	6.13e-05	0.000129	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HSPB1—kidney cancer	6.12e-05	0.000129	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EIF4EBP1—kidney cancer	6.12e-05	0.000129	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—RAF1—kidney cancer	6.1e-05	0.000128	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—RELA—kidney cancer	6.07e-05	0.000128	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB2—kidney cancer	6.04e-05	0.000127	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD8A—kidney cancer	6.03e-05	0.000127	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CTNNB1—kidney cancer	5.98e-05	0.000126	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MTOR—kidney cancer	5.96e-05	0.000125	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—MAPK3—kidney cancer	5.95e-05	0.000125	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CD4—kidney cancer	5.95e-05	0.000125	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN2B—kidney cancer	5.94e-05	0.000125	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PIK3CA—kidney cancer	5.88e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—RAF1—kidney cancer	5.86e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—RELA—kidney cancer	5.83e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB2—kidney cancer	5.8e-05	0.000122	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—MTOR—kidney cancer	5.72e-05	0.00012	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD4—kidney cancer	5.71e-05	0.00012	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TSC1—kidney cancer	5.69e-05	0.00012	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PSMD7—kidney cancer	5.69e-05	0.00012	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ANXA1—kidney cancer	5.69e-05	0.00012	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—MAPK1—kidney cancer	5.66e-05	0.000119	CbGpPWpGaD
Lithium—GSK3A—Disease—APC—kidney cancer	5.66e-05	0.000119	CbGpPWpGaD
Lithium—GSK3A—Disease—KIT—kidney cancer	5.66e-05	0.000119	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF2—kidney cancer	5.65e-05	0.000119	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDH1—kidney cancer	5.64e-05	0.000119	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN2B—kidney cancer	5.63e-05	0.000118	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CDKN1B—kidney cancer	5.59e-05	0.000118	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FLT1—kidney cancer	5.51e-05	0.000116	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF1R—kidney cancer	5.46e-05	0.000115	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDKN1B—kidney cancer	5.37e-05	0.000113	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KRAS—kidney cancer	5.35e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—JUN—kidney cancer	5.32e-05	0.000112	CbGpPWpGaD
Lithium—GSK3A—Disease—BRAF—kidney cancer	5.32e-05	0.000112	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CTNNB1—kidney cancer	5.28e-05	0.000111	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—kidney cancer	5.26e-05	0.000111	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PTEN—kidney cancer	5.15e-05	0.000108	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—kidney cancer	5.14e-05	0.000108	CbGpPWpGaD
Lithium—GSK3B—Immune System—TSC2—kidney cancer	5.13e-05	0.000108	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JUNB—kidney cancer	5.11e-05	0.000107	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PAK1—kidney cancer	5.11e-05	0.000107	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MAPK3—kidney cancer	4.98e-05	0.000105	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PTEN—kidney cancer	4.94e-05	0.000104	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PIK3CA—kidney cancer	4.91e-05	0.000103	CbGpPWpGaD
Lithium—GSK3A—Immune System—RAF1—kidney cancer	4.81e-05	0.000101	CbGpPWpGaD
Lithium—GSK3A—Immune System—RELA—kidney cancer	4.79e-05	0.000101	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB2—kidney cancer	4.76e-05	0.0001	CbGpPWpGaD
Lithium—GSK3B—Disease—HIF1A—kidney cancer	4.75e-05	9.98e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MAPK1—kidney cancer	4.74e-05	9.97e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—TSC2—kidney cancer	4.73e-05	9.96e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PIK3CA—kidney cancer	4.72e-05	9.93e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MTOR—kidney cancer	4.7e-05	9.88e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD4—kidney cancer	4.69e-05	9.86e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KIT—kidney cancer	4.53e-05	9.52e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HIF1A—kidney cancer	4.5e-05	9.46e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TSC2—kidney cancer	4.49e-05	9.44e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—kidney cancer	4.48e-05	9.41e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—RAF1—kidney cancer	4.44e-05	9.34e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1B—kidney cancer	4.41e-05	9.27e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MAPK3—kidney cancer	4.4e-05	9.25e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB2—kidney cancer	4.39e-05	9.24e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MTOR—kidney cancer	4.34e-05	9.12e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CD4—kidney cancer	4.33e-05	9.1e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL2—kidney cancer	4.31e-05	9.07e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KDR—kidney cancer	4.3e-05	9.05e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—kidney cancer	4.3e-05	9.03e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—JUN—kidney cancer	4.19e-05	8.82e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MAPK1—kidney cancer	4.18e-05	8.8e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KIT—kidney cancer	4.18e-05	8.79e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—APC—kidney cancer	4.18e-05	8.79e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF2—kidney cancer	4.17e-05	8.78e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDH1—kidney cancer	4.17e-05	8.77e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTNNB1—kidney cancer	4.16e-05	8.76e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN2B—kidney cancer	4.16e-05	8.74e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1B—kidney cancer	4.07e-05	8.56e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PTEN—kidney cancer	4.06e-05	8.53e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1R—kidney cancer	4.04e-05	8.49e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KIT—kidney cancer	3.96e-05	8.33e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APC—kidney cancer	3.96e-05	8.33e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—kidney cancer	3.95e-05	8.31e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—BRAF—kidney cancer	3.93e-05	8.27e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CTNNB1—kidney cancer	3.84e-05	8.08e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—kidney cancer	3.8e-05	7.98e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—POMC—kidney cancer	3.77e-05	7.93e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PTEN—kidney cancer	3.75e-05	7.88e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BRAF—kidney cancer	3.72e-05	7.83e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CA—kidney cancer	3.63e-05	7.64e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—RAF1—kidney cancer	3.55e-05	7.47e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—RELA—kidney cancer	3.54e-05	7.44e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB2—kidney cancer	3.52e-05	7.4e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CA—kidney cancer	3.49e-05	7.33e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MTOR—kidney cancer	3.47e-05	7.3e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MAPK3—kidney cancer	3.47e-05	7.29e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD4—kidney cancer	3.46e-05	7.28e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HIF1A—kidney cancer	3.32e-05	6.99e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TSC2—kidney cancer	3.31e-05	6.97e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MAPK1—kidney cancer	3.3e-05	6.94e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—RAF1—kidney cancer	3.28e-05	6.9e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1B—kidney cancer	3.26e-05	6.85e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB2—kidney cancer	3.25e-05	6.83e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MTOR—kidney cancer	3.2e-05	6.74e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MAPK3—kidney cancer	3.2e-05	6.73e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CD4—kidney cancer	3.2e-05	6.73e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL2—kidney cancer	3.19e-05	6.7e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KDR—kidney cancer	3.18e-05	6.68e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—kidney cancer	3.17e-05	6.68e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—kidney cancer	3.12e-05	6.55e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—kidney cancer	3.11e-05	6.55e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RAF1—kidney cancer	3.11e-05	6.54e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—JUN—kidney cancer	3.1e-05	6.52e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RELA—kidney cancer	3.1e-05	6.51e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB2—kidney cancer	3.08e-05	6.47e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTNNB1—kidney cancer	3.08e-05	6.47e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MAPK1—kidney cancer	3.05e-05	6.41e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MTOR—kidney cancer	3.04e-05	6.39e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1B—kidney cancer	3.01e-05	6.32e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTEN—kidney cancer	3e-05	6.31e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KIT—kidney cancer	2.93e-05	6.16e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APC—kidney cancer	2.93e-05	6.16e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—kidney cancer	2.88e-05	6.05e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CA—kidney cancer	2.86e-05	6.02e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1B—kidney cancer	2.85e-05	5.99e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CTNNB1—kidney cancer	2.84e-05	5.97e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL2—kidney cancer	2.79e-05	5.86e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—POMC—kidney cancer	2.79e-05	5.86e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTEN—kidney cancer	2.77e-05	5.82e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BRAF—kidney cancer	2.75e-05	5.79e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—kidney cancer	2.72e-05	5.72e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—JUN—kidney cancer	2.71e-05	5.7e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNB1—kidney cancer	2.69e-05	5.66e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CA—kidney cancer	2.64e-05	5.56e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTEN—kidney cancer	2.62e-05	5.52e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAPK3—kidney cancer	2.56e-05	5.39e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAPK1—kidney cancer	2.44e-05	5.13e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—kidney cancer	2.37e-05	4.98e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MAPK3—kidney cancer	2.37e-05	4.97e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—kidney cancer	2.3e-05	4.84e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—kidney cancer	2.3e-05	4.84e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RAF1—kidney cancer	2.3e-05	4.83e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RELA—kidney cancer	2.29e-05	4.81e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB2—kidney cancer	2.27e-05	4.78e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MAPK1—kidney cancer	2.25e-05	4.73e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MTOR—kidney cancer	2.24e-05	4.72e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK3—kidney cancer	2.24e-05	4.71e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—kidney cancer	2.18e-05	4.59e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK1—kidney cancer	2.13e-05	4.49e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—kidney cancer	2.13e-05	4.47e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CA—kidney cancer	2.12e-05	4.45e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1B—kidney cancer	2.11e-05	4.43e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2—kidney cancer	2.06e-05	4.33e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—kidney cancer	2.01e-05	4.24e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—kidney cancer	2.01e-05	4.22e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JUN—kidney cancer	2e-05	4.22e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNB1—kidney cancer	1.99e-05	4.18e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CA—kidney cancer	1.95e-05	4.11e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTEN—kidney cancer	1.94e-05	4.08e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CA—kidney cancer	1.85e-05	3.89e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—kidney cancer	1.79e-05	3.77e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—kidney cancer	1.75e-05	3.68e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK3—kidney cancer	1.66e-05	3.48e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—kidney cancer	1.61e-05	3.39e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK1—kidney cancer	1.58e-05	3.31e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—kidney cancer	1.49e-05	3.13e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CA—kidney cancer	1.37e-05	2.88e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—kidney cancer	1.32e-05	2.78e-05	CbGpPWpGaD
